Skip to content

Expression of IRAK1 Gene rs1059703-related Single- Nucleotide Polymorphisms in Egyptian Patient With Rheumatoid Arthritis

Expression of IRAK1 Gene rs1059703-related Single- Nucleotide Polymorphisms in Egyptian Patient With Rheumatoid Arthritis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05588817
Enrollment
90
Registered
2022-10-20
Start date
2022-12-30
Completion date
2023-12-01
Last updated
2022-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis (RA)

Brief summary

Rheumatoid arthritis (RA) is known as a long-lasting inflammatory autoimmune disease affecting the diarthrodial joints, which is diagnosed by inflammation and hyperplasia in synovium, generation of RF and anti-citrullinated protein antibody (ACPA), deformity of cartilage and bone, systemic injuries involving cardiovascular, pulmonary, psychological, and skeletal disorders (McInnes and Schett., 2011).

Interventions

GENETICPCR polymorphism

PCR polymorphism in Rhomatoid arthritis patients in Egypt

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
17 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* approval to sign an informed written consent, patient diagnosed rheumatoid arthritis, patient age range 17-85 year and both sexes are included.

Exclusion criteria

* Refusal to sign an informed written consent and patient with other autoimmune disease.

Design outcomes

Primary

MeasureTime frameDescription
rs1059703 PCR polymorphism in rhomatoid arthritis patients1 yearPCR polymorphism

Countries

Egypt

Contacts

Primary ContactAlaa A Abdel salam, Assistant lecturer
alaa.eisa@med.sohag.edu.eg01099058889
Backup ContactEsam M Abulfadl, Professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026